What Fasturtec Treats: Main Uses and Benefits

Rasburicase is commonly used to address acute symptomatic episodes, relevant in situations where patients face a high risk of developing severe conditions during cancer therapy. The medication is used to treat and help with high levels of uric acid in the blood to help address the risk of kidney failure.

---

Managing Acute Hyperuricemia and Tumor Lysis Syndrome Risk

This domain covers the medication's use in rapidly intervening against acute hyperuricemia, which is characterized by high levels of uric acid. It is applied when patients are undergoing cytoreductive chemotherapy for malignancies like leukemias and lymphomas, where a rapid surge of metabolites is anticipated or has begun. The therapeutic benefit is to manage this acute symptomatic condition and assists with easing the overall symptom burden by contributing to the rapid reduction of uric acid levels.

Quick Fact: Support for Acute Symptom Manifestation	Feature	Benefit
Therapeutic Focus	Management of high uric acid levels
Context	High-risk chemotherapy scenarios
Supportive Aim	Supportive care during cell breakdown

---

Addressing the Risk of Uric Acid-Induced Kidney Damage

The supportive role is applied in addressing the risk of a severe complication: acute kidney injury or renal failure. This application is relevant in high-risk clinical settings where patients need short-term symptomatic assistance and supports vital organ function. The medication supports a sense of stability, supporting the patient during difficult episodes and assists with maintaining functional stability. Indications for its use include the management of acute hyperuricemia and the prophylaxis (prevention) of complications associated with Tumor Lysis Syndrome (TLS).

“This supportive therapeutic approach helps patients cope more steadily with the difficult symptomatic phases of intensive treatment.”

Regulatory References

1. European Medicines Agency therapeutic overview

Who can and cannot use Fasturtec?

The eligibility for Fasturtec (Rasburicase) is strictly defined by regulatory authorities and depends on a patient's medical history and current physiological status.

Absolute Contraindications (Must Not Use)

Fasturtec is contraindicated in patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency or other cellular metabolic disorders known to cause haemolytic anaemia. Patients with a known history of anaphylaxis, severe hypersensitivity to rasburicase, or those who previously experienced a hemolytic reaction or methemoglobinemia after rasburicase administration must not use the medicine.

Approved Populations

The medicine is approved for use in both adult and pediatric patients being treated for malignancies (leukemia, lymphoma, and solid tumors) that put them at risk for elevated uric acid levels. Patients with renal impairment or hepatic impairment remain eligible for use based on official documentation, as no dose adjustment is necessary.

Use Restrictions

Fasturtec should not be used during pregnancy or breastfeeding. It is also not recommended for women of childbearing potential who are not using effective contraception. Regulatory documents indicate there is insufficient data to recommend multiple treatment courses.

Official Interaction Profile

The official regulatory documents for rasburicase define its interaction profile based primarily on patient metabolic status, required administration procedures, and potential laboratory interference, rather than common drug metabolism pathways.

Formal Prohibitions and Restrictions

• Contraindicated Metabolic Conditions: Use is formally prohibited (contraindicated) in individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency or other cellular metabolic disorders known to cause haemolytic anaemia. Patients at higher risk for G6PD deficiency should be screened prior to administration.
• Physical Incompatibility: The medicine is incompatible with and must never be diluted using glucose solutions (dextrose).
• Timing and Separation Rules: Rasburicase must be infused through a separate intravenous line from other chemotherapeutic agents to prevent possible drug incompatibility.

Pharmacokinetic and Substance Interaction Status

• Metabolic Interactions: No metabolic drug–drug interactions are generally anticipated with co-administered medicines, including agents such as allopurinol or methotrexate, as the enzyme is not expected to interfere with the cytochrome P450 system.
• Additive Risk: The labels note a potential for additive risk when used with substances that may induce methemoglobinemia.
• Laboratory Interference: The medicine degrades uric acid ex vivo in samples; therefore, blood samples for uric acid measurement require mandatory special handling procedures (chilling and prompt assay) to ensure accurate results.

The overall interaction structure is primarily defined by contraindications related to patient condition and mandatory procedural constraints for administration and laboratory testing.

Mechanism of Action (Pharmacodynamics)

The core mechanism of Fasturtec involves Enzymatic Catalysis by its active ingredient, Rasburicase, a recombinant form of the enzyme urate oxidase. This enzyme acts directly on the metabolite Uric Acid in the systemic circulation, catalyzing its immediate O2-dependent oxidation, a process termed Uricolysis.

This catabolic action converts poorly water-soluble uric acid into the highly water-soluble product, Allantoin. This resulting solubility shift facilitates efficient renal clearance. The rapid decrease in plasma uric acid establishes a steep concentration gradient, which functions as the physiological driver for mobilizing crystallized uric acid stores from tissues back into the circulation for subsequent breakdown and excretion. The mechanism is constrained by potential anti-drug antibody (ADA) neutralization and the generation of the byproduct Hydrogen Peroxide (H₂O₂), a reactive oxygen species.

Fasturtec (rasburicase) is administered as an intravenous infusion under the supervision of a physician trained in the chemotherapy of hematological malignancies.

Dosage and Administration

Parameter	Detail
Recommended Dose	0.20 mg per kg of body weight per day
Route of Administration	Once daily intravenous infusion in 50 mL of 0.9% sodium chloride solution
Infusion Duration	30 minutes
Treatment Duration	Up to 7 days, based on plasma uric acid levels and clinical judgment

Important Considerations

• Timing: Fasturtec is typically used immediately prior to and during the initiation of chemotherapy. It does not require any change to the timing or schedule of the chemotherapy.
• Infusion Line: The drug must be infused through a separate intravenous line from that used for chemotherapeutic agents to avoid incompatibility. If a separate line is not feasible, the existing line should be thoroughly flushed with saline solution before and after the Fasturtec infusion.
• Monitoring: Patients should be closely monitored for signs of hypersensitivity reactions, as well as for the onset of hemolysis or methemoglobinemia, especially in patients with or at high risk for Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, a contraindication for use. Uric acid levels must also be strictly monitored using a specific sample-handling procedure (collecting blood in pre-chilled tubes and immediately placing the sample in an ice water bath) to ensure accurate results.
• Pregnancy: The drug is not recommended for use during pregnancy or in women of childbearing potential not using contraception.

Fasturtec: Recent Clinical Evidence

The recombinant urate oxidase enzyme rasburicase (Fasturtec) has been the subject of multiple clinical trials, primarily focusing on its use in managing and preventing hyperuricemia (high uric acid levels) that is associated with Tumor Lysis Syndrome (TLS). TLS is a serious complication that can occur during the initiation of chemotherapy for certain blood cancers, such as leukemia and lymphoma.

Efficacy in Uric Acid Reduction

Clinical studies have consistently demonstrated the rapid and significant efficacy of rasburicase in reducing plasma uric acid (PUA) levels. In one major comparative study, patients at high risk for TLS who received rasburicase had a lower average blood level of uric acid over the first 96 hours of treatment compared to those who received allopurinol. Rasburicase functions by converting uric acid into allantoin, a more soluble product that is easily excreted by the kidneys. This rapid action is considered crucial for preventing uric acid crystal precipitation and subsequent kidney damage.

Safety and Special Populations

Research has highlighted important safety considerations. Due to the drug's mechanism, which produces hydrogen peroxide as a byproduct, there is a risk of hemolysis (red blood cell breakdown) and methemoglobinemia. Consequently, the drug is contraindicated in patients with known Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency and other metabolic disorders that predispose to hemolytic anemia.

Commonly reported adverse events in clinical trials included fever, headache, nausea, and vomiting. Monitoring of uric acid levels and renal function is standard practice during administration. There is currently limited data available on the safety or efficacy of multiple, repeated courses of the drug.

Key Studies & References Rasburicase for the Management of Hyperuricemia in Tumor Lysis Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Common questions about Fasturtec (FAQ)

Q: What is Fasturtec and what is it used for?

A: Fasturtec (rasburicase) is a medicine used to prevent and treat high levels of uric acid (hyperuricemia) in the blood. Hyperuricemia is a condition that can occur at the start of chemotherapy treatment for certain cancers of the blood, such as leukemia and lymphoma.

This rapid increase in uric acid is caused by the breakdown of cancer cells during treatment, a complication known as Tumor Lysis Syndrome (TLS). Fasturtec works by converting uric acid into a substance called allantoin, which is easier for the kidneys to flush out of the body.

Q: How is Fasturtec administered?

A: Fasturtec is given as an intravenous (IV) infusion (a drip into a vein) over 30 minutes. It is only administered by a healthcare professional, such as a doctor or nurse, in a hospital setting.

Q: How quickly does Fasturtec start to work?

A: Fasturtec works very quickly. Studies show that a single dose can significantly reduce uric acid levels within 4 hours of administration.

Q: What is the typical treatment course with Fasturtec?

A: Fasturtec is typically used as a short course of treatment, usually for one to seven days. The exact duration depends on the patient's uric acid levels and the doctor's assessment of how well the treatment is working. The goal is to control the high uric acid levels caused by chemotherapy.

Q: What are some important safety considerations for Fasturtec?

A: Important safety considerations include:

• Allergic Reactions: Serious allergic (hypersensitivity) reactions, including anaphylaxis, can occur. Patients are monitored during the infusion for signs such as rash, breathing difficulties, or swelling.
• Hemolysis: In rare cases, Fasturtec can cause the breakdown of red blood cells (hemolysis), particularly in patients with a genetic condition called glucose-6-phosphate dehydrogenase (G6PD) deficiency. Before treatment, patients may be tested for G6PD deficiency.
• Methemoglobinemia: This is another rare, but serious, condition where too much methemoglobin builds up in the blood, reducing oxygen delivery to the body's tissues.

Your healthcare provider will monitor you closely while you are receiving Fasturtec to manage these risks.

Storage and Disposal Instructions for Fasturtec (rasburicase)

Official regulatory labeling outlines strict conditions for the storage and disposal of Fasturtec, which is supplied as a lyophilized powder and solvent.

Storage Requirements

The unopened vials of powder and solvent must be stored in a refrigerator at a constant temperature between 2°C and 8°C (36°F and 46°F). It is mandatory to keep the product in its original package to ensure protection from light, and the vials must not be frozen at any time. The medicine must also be stored out of the sight and reach of children.

Stability and Disposal

While immediate use is preferred, the stability of the reconstituted and diluted solution is limited to a maximum of 24 hours if stored under refrigeration. Any unused or expired Fasturtec must be disposed of according to local regulatory requirements and should not be placed in household waste or wastewater.